To our knowledge, this study is the first to directly compare CSFAβ42 + /amyR − and CSFAβ42 + /amyR + patients, as well as the first to examine differences and overlap between them, healthy controls, and A + T + in terms of CSF p-tau, AD-related burden, and brain FDG-PET metabolic patterns. This evidence concerns the gene MAPT and Alzheimer disease.